Connect with us


Industry leader to educate UK doctors about medical cannabis



A global industry leader is expanding its e-learning platform to reach doctors in the UK.

Khiron Life Sciences, which has core operations in Latin America and expanding activity in Europe, has partnered with the Medical Cannabis Clinicians Society (MCCS) to provide training for UK doctors.

Under the agreement, Khiron will provide medical cannabis knowledge and training through its cloud-based learning platform to participating doctors across the country.

The Khiron medical cannabis program begins with online courses for MCCS participants, introducing doctors in the UK to specific regulatory considerations, clinical evidence and research, safety and drug interactions, clinical cases and practical recommendations to best meet patient needs for conditions that include chronic pain, anxiety, cancer and epilepsy.

Doctors participating in this program are also members of Project Twenty21, the leading medical cannabis registry in the UK.

Tejinder Virk, Khiron Europe President commented: “Doctor education continues to be a core mission for Khiron. Through this partnership with MCCS our e-learning program and highly trained medical team will now bring our successful medical cannabis knowledge to UK doctors so that they in turn can better meet patient needs.

“A lack of doctor education has been missing in growing the UK medical cannabis market and we are pleased to participate in helping the medical community overcome this barrier.”

In November 2018 the UK legalized medical cannabis, establishing a market opportunity to reach and positively impact the lives of a population of over 66 million according to Prohibition Partners UK Report.

More than 1.4 million people in the UK said to be using ‘street’ cannabis for chronic pain alone and the number of prescriptions expected to increase as access to medical cannabis expands, and doctors receive more education on suitable applications.

By 2024, the UK medical cannabis market is predicted to be worth nearly £1 billion servicing nearly 340,000 active patients.

The Medical Cannabis Clinicians Society is a non-profit organisation where clinicians can share practical knowledge, develop transparent and independent guidance and lead the conversation as doctors in the sector.

Professor Mike Barnes, Chair of the Medical Cannabis Clinicians Society said: “We know that education is critically important in helping doctors issue safe and effective medical cannabis prescriptions for certain conditions.

“Partnering with Khiron is invaluable for MCCS in allowing our members to work with the company’s globally validated e-learning platform to inform doctors and to improve the quality of UK patient lives through medical cannabis.”


Sarah Sinclair is a respected cannabis journalist writing on subjects related to science, medicine, research, health and wellness. She is managing editor of Cannabis Health, the UK’s leading title covering medical cannabis and CBD, and sister title and Psychedelic Health. Sarah has an NCTJ journalism qualification and an MA in Journalism from the University of Sunderland. Sarah has over six years experience working on newspapers, magazines and digital-first titles, the last two of which have been in the cannabis sector. She has also completed training through the Medical Cannabis Clinicians Society securing a certificate in Medical Cannabis Explained. She is a member of PLEA’s (Patient-Led Engagement for Access) advisory board, has hosted several webinars on cannabis and women's health and has moderated at industry events such as Cannabis Europa. Sarah Sinclair is the editor of Cannabis Health. Got a story? Email / Follow us on Twitter: @CannabisHNews / Instagram: @cannabishealthmag


Cannabis Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. All content on this site is intended for educational purposes, please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2024 PP Intelligence Ltd.